What To Do About Caronia
This article was originally published in RPM Report
While pharmaceutical marketers wait to hear how the government will respond to the Second Circuit’s off-label communication Caronia court ruling, PhRMA is considering ways to take the initiative. On the table: working proactively with FDA to re-frame the rules around off-label promotion.
You may also be interested in...
If firms could promote drugs for uses not backed by well-controlled studies, it would be “a nightmare,” Temple says; AEI’s Scott Gottlieb suggests the agency might try to regulate how medicines are prescribed.
In a watershed decision, a federal appeals court declares that manufacturers cannot be prosecuted under the FD&C Act’s misbranding provisions solely for speech promoting off-label use of a drug. Industry attorneys predict the decision, if it stands, will change the government’s approach to pursuing such cases.
ClinROs, artificial intelligence-based algorithms will be included in approval pathway. FDA is taking a crash course on new techniques for trial assessment thanks to COVID.